Xing Li, PhD
Inova Schar Cancer Institute
Fairfax, VA
Multi-site contributions to reporting | |||||
Main site | Satellite A | Satellite B | Satellite C | Satellite D | |
57.1% | 8.3% | 23.8% | 6.0% | 4.8% | |
Treatment modalities included in reporting | |||||
Brachytherapy | Radiopharmaceutical | Photon | Proton | Others | |
16.7% | 0.0% | 47.6% | 16.7% | 19.0% | |
Types of incidences | |||||
Therapeutic Radiation Incident | Other Safety Incident | Near miss | Unsafe condition | Process Improvement | Irrelevant |
10.7% | 14.3% | 26.2% | 13.1% | 26.2% | 9.5% |
Harm score | |||||
No harm | Mild/Temporary harm | Severe/Permanent harm | Death | ||
89.7% | 10.3% | 0.0% | 0.0% |